OpenAccessBelV2, PascalFrancis, Curation, bibRecord, 000050

Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation

Identifieur interne : 000050 ( PascalFrancis/Curation ); précédent : 000049; suivant : 000051

Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation

Auteurs : Sheila A. R. Kort [Pays-Bas] ; Frans Martens [Pays-Bas] ; Hilde Vanpoucke [Belgique] ; Hans L. Van Duijnhoven [Pays-Bas] ; Marinus A. Blankenstein [Pays-Bas]

Source :

Clinical chemistry : (Baltimore, Md.) [ 0009-9147 ] ; 2006.

RBID : Pascal:06-0468763

Descripteurs français

Pascal (Inist)
- Etude comparative, Analyse automatique, Forme libre, Antigène spécifique prostate, Marqueur tumoral, Référence, Réactivité, OMS, Préparation, Biochimie, Biologie clinique, Biologie moléculaire.
Wicri :
- topic : Biochimie.

English descriptors

KwdEn :
- Automatic analysis, Biochemistry, Clinical biology, Comparative study, Free form, Molecular biology, Preparation, Prostate specific antigen, Reactivity, Reference, Tumoral marker, WHO.

Abstract

Background: Prostate-specific antigen (PSA) assays have historically produced different results. Our aim was to investigate the comparability of assay results of selected commercially available assay methods designed to measure total, free, or complexed PSA (tPSA, fPSA, and cPSA). Methods: We measured tPSA, fPSA, and cPSA in 70 samples and in the WHO PSA 96/670 reference preparation with 6 assays (Beckman-Coulter Access, Abbott ARCHITECT and AxSYM, Bayer Advia Centaur, DPC IMMULITE 2000, and Roche Modular Analytics E170). We also calculated the fPSA/tPSA ratio. Results: The mean deviations from the expected tPSA and fPSA values for the WHO 96/670 reference preparation were 0.37 (range, 0.01-1.32) and 0.19 (range, 0.05-0.49) μg/L, respectively. When plotted against the expected WHO 96/670 reference preparation value, regression slopes varied from 0.99 to 1.22 and r2 from 0.9996 to 1.000. When total PSA was measured in mixtures of sera with high and low tPSA concentrations, the mean (SD) slope of regression of different assays against an in-house method was 1.04 (0.09). In these specimens, the fPSA/tPSA ratio was 0.11-0.14 with different methods. The tPSA and fPSA values in patient samples measured in different assays and plotted against ARCHITECT gave regression slopes from 0.88 to 0.97. The results of the studied assays for tPSA in serum samples agreed within 15%, from each other, and all results for the WHO 96/670 reference preparation were within 6.8% (confidence interval, 1.7%-15.2%) of the expected value. The results for fPSA were more diverse. Conclusions: Differences among PSA assays appear to have decreased since introduction of the WHO 96/670 reference preparation, but further efforts are needed to harmonize fPSA assays.

A01	`01`	`1`		`@0 0009-9147`
A02	`01`			`@0 CLCHAU`
A03		`1`		`@0 Clin. chem. : (Baltim. Md.)`
A05				`@2 52`
A06				`@2 8`
A08	`01`	`1`	`ENG`	`@1 Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation`
A11	`01`	`1`		`@1 KORT (Sheila A. R.)`
A11	`02`	`1`		`@1 MARTENS (Frans)`
A11	`03`	`1`		`@1 VANPOUCKE (Hilde)`
A11	`04`	`1`		`@1 VAN DUIJNHOVEN (Hans L.)`
A11	`05`	`1`		`@1 BLANKENSTEIN (Marinus A.)`
A14	`01`			`@1 Endocrine Laboratory, Department of Clinical Chemistry, VU University Medical Center @2 Amsterdam @3 NLD @Z 1 aut. @Z 2 aut. @Z 5 aut.`
A14	`02`			`@1 Laboratory of Clinical Chemistry, H. Hartziekenhuis @2 Roeselare-Menen vzw @3 BEL @Z 3 aut.`
A14	`03`			`@1 Algemeen Klinisch Laboratorium, Elkerliek Ziekenhuis @2 Helmond @3 NLD @Z 4 aut.`
A20				`@1 1568-1574`
A21				`@1 2006`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 7603 @5 354000133385130160`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 19 ref.`
A47	`01`	`1`		`@0 06-0468763`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Clinical chemistry : (Baltimore, Md.)`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Background: Prostate-specific antigen (PSA) assays have historically produced different results. Our aim was to investigate the comparability of assay results of selected commercially available assay methods designed to measure total, free, or complexed PSA (tPSA, fPSA, and cPSA). Methods: We measured tPSA, fPSA, and cPSA in 70 samples and in the WHO PSA 96/670 reference preparation with 6 assays (Beckman-Coulter Access, Abbott ARCHITECT and AxSYM, Bayer Advia Centaur, DPC IMMULITE 2000, and Roche Modular Analytics E170). We also calculated the fPSA/tPSA ratio. Results: The mean deviations from the expected tPSA and fPSA values for the WHO 96/670 reference preparation were 0.37 (range, 0.01-1.32) and 0.19 (range, 0.05-0.49) μg/L, respectively. When plotted against the expected WHO 96/670 reference preparation value, regression slopes varied from 0.99 to 1.22 and r2 from 0.9996 to 1.000. When total PSA was measured in mixtures of sera with high and low tPSA concentrations, the mean (SD) slope of regression of different assays against an in-house method was 1.04 (0.09). In these specimens, the fPSA/tPSA ratio was 0.11-0.14 with different methods. The tPSA and fPSA values in patient samples measured in different assays and plotted against ARCHITECT gave regression slopes from 0.88 to 0.97. The results of the studied assays for tPSA in serum samples agreed within 15%, from each other, and all results for the WHO 96/670 reference preparation were within 6.8% (confidence interval, 1.7%-15.2%) of the expected value. The results for fPSA were more diverse. Conclusions: Differences among PSA assays appear to have decreased since introduction of the WHO 96/670 reference preparation, but further efforts are needed to harmonize fPSA assays.
C02	`01`	`X`		`@0 002B24`
C02	`02`	`X`		`@0 002A02`
C03	`01`	`X`	`FRE`	`@0 Etude comparative @5 02`
C03	`01`	`X`	`ENG`	`@0 Comparative study @5 02`
C03	`01`	`X`	`SPA`	`@0 Estudio comparativo @5 02`
C03	`02`	`X`	`FRE`	`@0 Analyse automatique @5 03`
C03	`02`	`X`	`ENG`	`@0 Automatic analysis @5 03`
C03	`02`	`X`	`SPA`	`@0 Análisis automático @5 03`
C03	`03`	`X`	`FRE`	`@0 Forme libre @5 05`
C03	`03`	`X`	`ENG`	`@0 Free form @5 05`
C03	`03`	`X`	`SPA`	`@0 Forma libre @5 05`
C03	`04`	`X`	`FRE`	`@0 Antigène spécifique prostate @5 06`
C03	`04`	`X`	`ENG`	`@0 Prostate specific antigen @5 06`
C03	`04`	`X`	`SPA`	`@0 Antigeno específico prostata @5 06`
C03	`05`	`X`	`FRE`	`@0 Marqueur tumoral @5 08`
C03	`05`	`X`	`ENG`	`@0 Tumoral marker @5 08`
C03	`05`	`X`	`SPA`	`@0 Marcador tumoral @5 08`
C03	`06`	`X`	`FRE`	`@0 Référence @5 09`
C03	`06`	`X`	`ENG`	`@0 Reference @5 09`
C03	`06`	`X`	`SPA`	`@0 Referencia @5 09`
C03	`07`	`X`	`FRE`	`@0 Réactivité @5 11`
C03	`07`	`X`	`ENG`	`@0 Reactivity @5 11`
C03	`07`	`X`	`SPA`	`@0 Reactividad @5 11`
C03	`08`	`X`	`FRE`	`@0 OMS @5 12`
C03	`08`	`X`	`ENG`	`@0 WHO @5 12`
C03	`08`	`X`	`SPA`	`@0 OMS @5 12`
C03	`09`	`X`	`FRE`	`@0 Préparation @5 14`
C03	`09`	`X`	`ENG`	`@0 Preparation @5 14`
C03	`09`	`X`	`SPA`	`@0 Preparación @5 14`
C03	`10`	`X`	`FRE`	`@0 Biochimie @5 15`
C03	`10`	`X`	`ENG`	`@0 Biochemistry @5 15`
C03	`10`	`X`	`SPA`	`@0 Bioquímica @5 15`
C03	`11`	`X`	`FRE`	`@0 Biologie clinique @5 17`
C03	`11`	`X`	`ENG`	`@0 Clinical biology @5 17`
C03	`11`	`X`	`SPA`	`@0 Biología clínica @5 17`
C03	`12`	`X`	`FRE`	`@0 Biologie moléculaire @5 18`
C03	`12`	`X`	`ENG`	`@0 Molecular biology @5 18`
C03	`12`	`X`	`SPA`	`@0 Biología molecular @5 18`
N21				`@1 310`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000106

Links to Exploration step

Pascal:06-0468763

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation</title>
<author><name sortKey="Kort, Sheila A R" sort="Kort, Sheila A R" uniqKey="Kort S" first="Sheila A. R." last="Kort">Sheila A. R. Kort</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Endocrine Laboratory, Department of Clinical Chemistry, VU University Medical Center</s1>
<s2>Amsterdam</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Martens, Frans" sort="Martens, Frans" uniqKey="Martens F" first="Frans" last="Martens">Frans Martens</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Endocrine Laboratory, Department of Clinical Chemistry, VU University Medical Center</s1>
<s2>Amsterdam</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Vanpoucke, Hilde" sort="Vanpoucke, Hilde" uniqKey="Vanpoucke H" first="Hilde" last="Vanpoucke">Hilde Vanpoucke</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Laboratory of Clinical Chemistry, H. Hartziekenhuis</s1>
<s2>Roeselare-Menen vzw</s2>
<s3>BEL</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Van Duijnhoven, Hans L" sort="Van Duijnhoven, Hans L" uniqKey="Van Duijnhoven H" first="Hans L." last="Van Duijnhoven">Hans L. Van Duijnhoven</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Algemeen Klinisch Laboratorium, Elkerliek Ziekenhuis</s1>
<s2>Helmond</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Blankenstein, Marinus A" sort="Blankenstein, Marinus A" uniqKey="Blankenstein M" first="Marinus A." last="Blankenstein">Marinus A. Blankenstein</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Endocrine Laboratory, Department of Clinical Chemistry, VU University Medical Center</s1>
<s2>Amsterdam</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0468763</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0468763 INIST</idno>
<idno type="RBID">Pascal:06-0468763</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000106</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000050</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation</title>
<author><name sortKey="Kort, Sheila A R" sort="Kort, Sheila A R" uniqKey="Kort S" first="Sheila A. R." last="Kort">Sheila A. R. Kort</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Endocrine Laboratory, Department of Clinical Chemistry, VU University Medical Center</s1>
<s2>Amsterdam</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Martens, Frans" sort="Martens, Frans" uniqKey="Martens F" first="Frans" last="Martens">Frans Martens</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Endocrine Laboratory, Department of Clinical Chemistry, VU University Medical Center</s1>
<s2>Amsterdam</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Vanpoucke, Hilde" sort="Vanpoucke, Hilde" uniqKey="Vanpoucke H" first="Hilde" last="Vanpoucke">Hilde Vanpoucke</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Laboratory of Clinical Chemistry, H. Hartziekenhuis</s1>
<s2>Roeselare-Menen vzw</s2>
<s3>BEL</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Van Duijnhoven, Hans L" sort="Van Duijnhoven, Hans L" uniqKey="Van Duijnhoven H" first="Hans L." last="Van Duijnhoven">Hans L. Van Duijnhoven</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Algemeen Klinisch Laboratorium, Elkerliek Ziekenhuis</s1>
<s2>Helmond</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Blankenstein, Marinus A" sort="Blankenstein, Marinus A" uniqKey="Blankenstein M" first="Marinus A." last="Blankenstein">Marinus A. Blankenstein</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Endocrine Laboratory, Department of Clinical Chemistry, VU University Medical Center</s1>
<s2>Amsterdam</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Clinical chemistry : (Baltimore, Md.)</title>
<title level="j" type="abbreviated">Clin. chem. : (Baltim. Md.)</title>
<idno type="ISSN">0009-9147</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Clinical chemistry : (Baltimore, Md.)</title>
<title level="j" type="abbreviated">Clin. chem. : (Baltim. Md.)</title>
<idno type="ISSN">0009-9147</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Automatic analysis</term>
<term>Biochemistry</term>
<term>Clinical biology</term>
<term>Comparative study</term>
<term>Free form</term>
<term>Molecular biology</term>
<term>Preparation</term>
<term>Prostate specific antigen</term>
<term>Reactivity</term>
<term>Reference</term>
<term>Tumoral marker</term>
<term>WHO</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Etude comparative</term>
<term>Analyse automatique</term>
<term>Forme libre</term>
<term>Antigène spécifique prostate</term>
<term>Marqueur tumoral</term>
<term>Référence</term>
<term>Réactivité</term>
<term>OMS</term>
<term>Préparation</term>
<term>Biochimie</term>
<term>Biologie clinique</term>
<term>Biologie moléculaire</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Biochimie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Prostate-specific antigen (PSA) assays have historically produced different results. Our aim was to investigate the comparability of assay results of selected commercially available assay methods designed to measure total, free, or complexed PSA (tPSA, fPSA, and cPSA). Methods: We measured tPSA, fPSA, and cPSA in 70 samples and in the WHO PSA 96/670 reference preparation with 6 assays (Beckman-Coulter Access, Abbott ARCHITECT and AxSYM, Bayer Advia Centaur, DPC IMMULITE 2000, and Roche Modular Analytics E170). We also calculated the fPSA/tPSA ratio. Results: The mean deviations from the expected tPSA and fPSA values for the WHO 96/670 reference preparation were 0.37 (range, 0.01-1.32) and 0.19 (range, 0.05-0.49) μg/L, respectively. When plotted against the expected WHO 96/670 reference preparation value, regression slopes varied from 0.99 to 1.22 and r2 from 0.9996 to 1.000. When total PSA was measured in mixtures of sera with high and low tPSA concentrations, the mean (SD) slope of regression of different assays against an in-house method was 1.04 (0.09). In these specimens, the fPSA/tPSA ratio was 0.11-0.14 with different methods. The tPSA and fPSA values in patient samples measured in different assays and plotted against ARCHITECT gave regression slopes from 0.88 to 0.97. The results of the studied assays for tPSA in serum samples agreed within 15%, from each other, and all results for the WHO 96/670 reference preparation were within 6.8% (confidence interval, 1.7%-15.2%) of the expected value. The results for fPSA were more diverse. Conclusions: Differences among PSA assays appear to have decreased since introduction of the WHO 96/670 reference preparation, but further efforts are needed to harmonize fPSA assays.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0009-9147</s0>
</fA01>
<fA02 i1="01"><s0>CLCHAU</s0>
</fA02>
<fA03 i2="1"><s0>Clin. chem. : (Baltim. Md.)</s0>
</fA03>
<fA05><s2>52</s2>
</fA05>
<fA06><s2>8</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>KORT (Sheila A. R.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MARTENS (Frans)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>VANPOUCKE (Hilde)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>VAN DUIJNHOVEN (Hans L.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>BLANKENSTEIN (Marinus A.)</s1>
</fA11>
<fA14 i1="01"><s1>Endocrine Laboratory, Department of Clinical Chemistry, VU University Medical Center</s1>
<s2>Amsterdam</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Laboratory of Clinical Chemistry, H. Hartziekenhuis</s1>
<s2>Roeselare-Menen vzw</s2>
<s3>BEL</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Algemeen Klinisch Laboratorium, Elkerliek Ziekenhuis</s1>
<s2>Helmond</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>1568-1574</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>7603</s2>
<s5>354000133385130160</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>19 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0468763</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Clinical chemistry : (Baltimore, Md.)</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: Prostate-specific antigen (PSA) assays have historically produced different results. Our aim was to investigate the comparability of assay results of selected commercially available assay methods designed to measure total, free, or complexed PSA (tPSA, fPSA, and cPSA). Methods: We measured tPSA, fPSA, and cPSA in 70 samples and in the WHO PSA 96/670 reference preparation with 6 assays (Beckman-Coulter Access, Abbott ARCHITECT and AxSYM, Bayer Advia Centaur, DPC IMMULITE 2000, and Roche Modular Analytics E170). We also calculated the fPSA/tPSA ratio. Results: The mean deviations from the expected tPSA and fPSA values for the WHO 96/670 reference preparation were 0.37 (range, 0.01-1.32) and 0.19 (range, 0.05-0.49) μg/L, respectively. When plotted against the expected WHO 96/670 reference preparation value, regression slopes varied from 0.99 to 1.22 and r2 from 0.9996 to 1.000. When total PSA was measured in mixtures of sera with high and low tPSA concentrations, the mean (SD) slope of regression of different assays against an in-house method was 1.04 (0.09). In these specimens, the fPSA/tPSA ratio was 0.11-0.14 with different methods. The tPSA and fPSA values in patient samples measured in different assays and plotted against ARCHITECT gave regression slopes from 0.88 to 0.97. The results of the studied assays for tPSA in serum samples agreed within 15%, from each other, and all results for the WHO 96/670 reference preparation were within 6.8% (confidence interval, 1.7%-15.2%) of the expected value. The results for fPSA were more diverse. Conclusions: Differences among PSA assays appear to have decreased since introduction of the WHO 96/670 reference preparation, but further efforts are needed to harmonize fPSA assays.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B24</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002A02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Etude comparative</s0>
<s5>02</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Comparative study</s0>
<s5>02</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Estudio comparativo</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Analyse automatique</s0>
<s5>03</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Automatic analysis</s0>
<s5>03</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Análisis automático</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Forme libre</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Free form</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Forma libre</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antigène spécifique prostate</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Prostate specific antigen</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antigeno específico prostata</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Marqueur tumoral</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Tumoral marker</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Marcador tumoral</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Référence</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Reference</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Referencia</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Réactivité</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Reactivity</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Reactividad</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>OMS</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>WHO</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>OMS</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Préparation</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Preparation</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Preparación</s0>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Biochimie</s0>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Biochemistry</s0>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Bioquímica</s0>
<s5>15</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Biologie clinique</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Clinical biology</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Biología clínica</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Biologie moléculaire</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Molecular biology</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Biología molecular</s0>
<s5>18</s5>
</fC03>
<fN21><s1>310</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000050 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000050 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Belgique
   |area=    OpenAccessBelV2
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:06-0468763
   |texte=   Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation
}}

This area was generated with Dilib version V0.6.25.
Data generation: Thu Dec 1 00:43:49 2016. Site generation: Wed Mar 6 14:51:30 2024

	Serveur d'exploration autour du libre accès en Belgique
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration autour du libre accès en Belgique

Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation

Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri